

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Previously Presented) A method for selectively inhibiting Cox-2 relative to Cox-1 comprising the steps of:
 - administering a pre-determined dose of processed *Morinda citrifolia* juice to a patient at a concentration percentage of 2.31 ; and
 - limiting undesired COX-1 inhibition relative to COX-2 inhibition.

2. (Cancelled)

3. (Original) The method of claim 1, wherein the *Morinda citrifolia* is in liquid form.

4. (Original) The method of claim 1, wherein the *Morinda citrifolia* is included as an ingredient in a food product.

5. (Original) The method of claim 1, wherein the *Morinda citrifolia* is in capsule form.

6. (Original) The method of claim 1, wherein said dose of *Morinda citrifolia* inhibits the production of COX-2 related prostaglandins that cause pain and inflammation and inhibits to a lesser extent, the production of COX-1 related prostaglandins.

7. (Original) The method of claim 1, wherein said dose of *Morinda citrifolia* is administered at a predetermined concentration.

8. (Original) The method of claim 7, wherein said *Morinda citrifolia* is included as an ingredient in another food product.

9. (Previously Presented) A method for selectively inhibiting Cox-2 relative to Cox-1 comprising the steps of:
 - obtaining a quantity of *Morinda citrifolia* juice and pulp;
 - filtering the wet pulp from the juice;

pasteurizing the juice; and

providing a therapeutic dose of said *Morinda citrifolia* juice for consumption at a concentration percentage of 2.31, wherein said *Morinda citrifolia* juice is limits undesired COX-1 inhibition relative to COX-2 inhibition.

10. (Original) The method of claim 9, wherein the *Morinda citrifolia* juice is included as an ingredient in a food product.
11. (Cancelled)
12. (Previously Presented) A method for selectively inhibiting Cox-2 relative to Cox-1 comprising the steps of:
 - obtaining a quantity of *Morinda citrifolia* juice and pulp;
 - filtering the wet pulp from the juice, wherein the wet pulp has a fiber content of from 10% to 40%, by weight;
 - pasteurizing the pulp; and
 - providing a therapeutic dose of said *Morinda citrifolia* pulp for consumption by a patient, wherein said *Morinda citrifolia* juice is administered at a concentration percentage of 2.31 for limiting undesired COX-1 inhibition relative to COX-2 inhibition.
13. (Original) The method of claim 12, wherein the *Morinda citrifolia* pulp is included as an ingredient in a food product.
14. (Cancelled)